{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:04:46Z","timestamp":1784883886349,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-026-00744-1","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:38:19Z","timestamp":1784882299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-6422","authenticated-orcid":false,"given":"Anna","family":"Zenno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"744_CR1","unstructured":"Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE\u00ae. (setmelanotide) for Patients with Acquired Hypothalamic Obesity. 2026. https:\/\/ir.rhythmtx.com\/news-releases\/news-release-details\/rhythm-pharmaceuticals-announces-fda-approval-imcivreer-1\/. Accessed 03\/19\/2026."},{"issue":"2","key":"744_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2265.2004.02196.x","volume":"62","author":"AM Pereira","year":"2005","unstructured":"Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, van Thiel SW, et al. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf). 2005;62(2):197\u2013204. https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02196.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"744_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/EJE-15-0422","volume":"173","author":"A Hoffmann","year":"2015","unstructured":"Hoffmann A, Bootsveld K, Gebhardt U, Daubenbuchel AM, Sterkenburg AS, Muller HL. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol. 2015;173(3):389\u201397. https:\/\/doi.org\/10.1530\/EJE-15-0422.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"744_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.6065\/apem.2017.22.3.189","volume":"22","author":"SY Jung","year":"2017","unstructured":"Jung SY, Lee YJ, Lee HJ, Lee YA, Moon JS, Ko JS, et al. Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma. Ann Pediatr Endocrinol Metab. 2017;22(3):189\u201396. https:\/\/doi.org\/10.6065\/apem.2017.22.3.189.","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"12","key":"744_CR5","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/ppul.25097","volume":"55","author":"I Iyigun","year":"2020","unstructured":"Iyigun I, Alikasifoglu A, Gonc N, Ozon A, Eryilmaz Polat S, Hizal M, et al. Obstructive sleep apnea in children with hypothalamic obesity: Evaluation of possible related factors. Pediatr Pulmonol. 2020;55(12):3532\u201340. https:\/\/doi.org\/10.1002\/ppul.25097.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"744_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2265.2010.03838.x","volume":"73","author":"RK Crowley","year":"2010","unstructured":"Crowley RK, Hamnvik OP, O\u2019Sullivan EP, Behan LA, Smith D, Agha A, et al. Morbidity and mortality in patients with craniopharyngioma after surgery. Clin Endocrinol (Oxf). 2010;73(4):516\u201321. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03838.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"744_CR7","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/oby.22315","volume":"26","author":"SR Rose","year":"2018","unstructured":"Rose SR, Horne VE, Bingham N, Jenkins T, Black J, Inge T. Hypothalamic Obesity: 4 Years of the International Registry of Hypothalamic Obesity Disorders. Obes (Silver Spring). 2018;26(11):1727\u201332. https:\/\/doi.org\/10.1002\/oby.22315.","journal-title":"Obes (Silver Spring)"},{"issue":"2","key":"744_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","volume":"23","author":"CL Roth","year":"2021","unstructured":"Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, et al. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab. 2021;23(2):363\u201373. https:\/\/doi.org\/10.1111\/dom.14224.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"744_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","volume":"89","author":"GR Bunin","year":"1998","unstructured":"Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998;89(4):547\u201351. https:\/\/doi.org\/10.3171\/jns.1998.89.4.0547.","journal-title":"J Neurosurg"},{"issue":"1","key":"744_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S2213-8587(24)00283-3","volume":"13","author":"J Argente","year":"2025","unstructured":"Argente J, Farooqi IS, Chowen JA, Kuhnen P, Lopez M, Morselli E, et al. Hypothalamic obesity: from basic mechanisms to clinical perspectives. Lancet Diabetes Endocrinol. 2025;13(1):57\u201368. https:\/\/doi.org\/10.1016\/S2213-8587(24)00283-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"744_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1152\/physrev.1979.59.3.719","volume":"59","author":"GA Bray","year":"1979","unstructured":"Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev. 1979;59(3):719\u2013809. https:\/\/doi.org\/10.1152\/physrev.1979.59.3.719.","journal-title":"Physiol Rev"},{"issue":"1","key":"744_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cmet.2015.05.008","volume":"22","author":"JJ An","year":"2015","unstructured":"An JJ, Liao GY, Kinney CE, Sahibzada N, Xu B. Discrete BDNF Neurons in the Paraventricular Hypothalamus Control Feeding and Energy Expenditure. Cell Metab. 2015;22(1):175\u201388. https:\/\/doi.org\/10.1016\/j.cmet.2015.05.008.","journal-title":"Cell Metab"},{"key":"744_CR13","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ25-0408","author":"HL Muller","year":"2025","unstructured":"Muller HL, Tanaka T, Hasegawa T, Isojima T, Mori J, Kurosaki M, et al. Diagnostic criteria for acquired hypothalamic obesity - international expert guidance document. Endocr J. 2025. https:\/\/doi.org\/10.1507\/endocrj.EJ25-0408.","journal-title":"Endocr J"},{"issue":"6","key":"744_CR14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/oby.21067","volume":"23","author":"CL Roth","year":"2015","unstructured":"Roth CL, Eslamy H, Werny D, Elfers C, Shaffer ML, Pihoker C, et al. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obes (Silver Spring). 2015;23(6):1226\u201333. https:\/\/doi.org\/10.1002\/oby.21067.","journal-title":"Obes (Silver Spring)"},{"issue":"6","key":"744_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1210\/endrev\/bnaf025","volume":"46","author":"HM van Santen","year":"2025","unstructured":"van Santen HM, Muller HL. Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity. Endocr Rev. 2025;46(6):891\u2013907. https:\/\/doi.org\/10.1210\/endrev\/bnaf025.","journal-title":"Endocr Rev"},{"issue":"1","key":"744_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/EJE-11-0158","volume":"165","author":"HL Muller","year":"2011","unstructured":"Muller HL, Gebhardt U, Teske C, Faldum A, Zwiener I, Warmuth-Metz M, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165(1):17\u201324. https:\/\/doi.org\/10.1530\/EJE-11-0158.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"744_CR17","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.clnu.2024.05.028","volume":"43","author":"I Van Roessel","year":"2024","unstructured":"Van Roessel I, Van Den Brink M, Dekker J, Ruitenburg-van Essen BG, Tissing WJE, van Santen HM. Feasibility, safety, and efficacy of dietary or lifestyle interventions for hypothalamic obesity: A systematic review. Clin Nutr. 2024;43(8):1798\u2013811. https:\/\/doi.org\/10.1016\/j.clnu.2024.05.028.","journal-title":"Clin Nutr"},{"issue":"12","key":"744_CR18","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1210\/jc.2016-2126","volume":"101","author":"R Brauner","year":"2016","unstructured":"Brauner R, Serreau R, Souberbielle JC, Pouillot M, Grouazel S, Recasens C, et al. Diazoxide in Children With Obesity After Hypothalamic-Pituitary Lesions: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2016;101(12):4825\u201333. https:\/\/doi.org\/10.1210\/jc.2016-2126.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"744_CR19","doi-asserted-by":"publisher","first-page":"417949","DOI":"10.1155\/2011\/417949","volume":"2011","author":"JK Hamilton","year":"2011","unstructured":"Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D. Hypothalamic Obesity following Craniopharyngioma Surgery: Results of a Pilot Trial of Combined Diazoxide and Metformin Therapy. Int J Pediatr Endocrinol. 2011;2011(1):417949. https:\/\/doi.org\/10.1155\/2011\/417949.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"7","key":"744_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2213-8587(25)00161-5","volume":"13","author":"MG Butler","year":"2025","unstructured":"Butler MG. New drug approved for hyperphagia in Prader-Willi syndrome. Lancet Diabetes Endocrinol. 2025;13(7):547\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(25)00161-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"744_CR21","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1210\/jc.2002-030003","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88(6):2586\u201392. https:\/\/doi.org\/10.1210\/jc.2002-030003.","journal-title":"J Clin Endocrinol Metab"},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"846880","DOI":"10.3389\/fendo.2022.846880","volume":"13","author":"P Dimitri","year":"2022","unstructured":"Dimitri P. Treatment of Acquired Hypothalamic Obesity: Now and the Future. Front Endocrinol (Lausanne). 2022;13:846880. https:\/\/doi.org\/10.3389\/fendo.2022.846880.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"744_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.4158\/EP.14.6.697","volume":"14","author":"FL Greenway","year":"2008","unstructured":"Greenway FL, Bray GA. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract. 2008;14(6):697\u2013703. https:\/\/doi.org\/10.4158\/EP.14.6.697.","journal-title":"Endocr Pract"},{"key":"744_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fendo.2011.00078","volume":"2","author":"CT Elfers","year":"2011","unstructured":"Elfers CT, Roth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Front Endocrinol (Lausanne). 2011;2:78. https:\/\/doi.org\/10.3389\/fendo.2011.00078.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"744_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000495851","volume":"12","author":"C Denzer","year":"2019","unstructured":"Denzer C, Denzer F, Lennerz BS, Vollbach H, Lustig RH, Wabitsch M. Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series. Obes Facts. 2019;12(1):91\u2013102. https:\/\/doi.org\/10.1159\/000495851.","journal-title":"Obes Facts"},{"key":"744_CR26","doi-asserted-by":"publisher","first-page":"845937","DOI":"10.3389\/fendo.2022.845937","volume":"13","author":"J van Schaik","year":"2022","unstructured":"van Schaik J, Welling MS, de Groot CJ, van Eck JP, Juriaans A, Burghard M, et al. Dextroamphetamine Treatment in Children With Hypothalamic Obesity. Front Endocrinol (Lausanne). 2022;13:845937. https:\/\/doi.org\/10.3389\/fendo.2022.845937.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"744_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/jpc.16351","volume":"59","author":"J Preddy","year":"2023","unstructured":"Preddy J, Smith-Wade S, Houghton K. Lisdexamphetamine as a novel therapy for hyperphagia in Prader-Willi syndrome. J Paediatr Child Health. 2023;59(3):570\u20132. https:\/\/doi.org\/10.1111\/jpc.16351.","journal-title":"J Paediatr Child Health"},{"issue":"8","key":"744_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/21532176251385703","volume":"21","author":"M Salama","year":"2025","unstructured":"Salama M, Hassan D, Pittock S, Kumar S. Weight Loss Effect of Lisdexamfetamine in Children with Severe Obesity: A Case Series. Child Obes. 2025;21(8):641\u20137. https:\/\/doi.org\/10.1177\/21532176251385703.","journal-title":"Child Obes"},{"issue":"7","key":"744_CR29","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/dom.14366","volume":"23","author":"FA Perez","year":"2021","unstructured":"Perez FA, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ, Roth CL. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. Diabetes Obes Metab. 2021;23(7):1532\u201341. https:\/\/doi.org\/10.1111\/dom.14366.","journal-title":"Diabetes Obes Metab"},{"key":"744_CR30","doi-asserted-by":"publisher","unstructured":"Singh A, Haq N, Yang M, Luckey S, Mansouri S, Campbell-Thompson M, et al. Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model. J Clin Invest. 2025;135(12). https:\/\/doi.org\/10.1172\/JCI184636.","DOI":"10.1172\/JCI184636"},{"issue":"5","key":"744_CR31","doi-asserted-by":"publisher","first-page":"e12546","DOI":"10.1111\/cob.12546","volume":"12","author":"S Ganawa","year":"2022","unstructured":"Ganawa S, Santhosh SH, Parry L, Syed AA. Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome. Clin Obes. 2022;12(5):e12546. https:\/\/doi.org\/10.1111\/cob.12546.","journal-title":"Clin Obes"},{"issue":"5","key":"744_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11102-025-01564-7","volume":"28","author":"E Gjersdal","year":"2025","unstructured":"Gjersdal E, Klit FO, Schmidt Ettrup K, Vestergaard P, Nielsen EH, Vistisen KN, et al. Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life. Pituitary. 2025;28(5):93. https:\/\/doi.org\/10.1007\/s11102-025-01564-7.","journal-title":"Pituitary"},{"issue":"5","key":"744_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11102-024-01429-5","volume":"27","author":"M Svendstrup","year":"2024","unstructured":"Svendstrup M, Rasmussen AK, Kistorp C, Klose M, Andreassen M. Semaglutide treatment of hypothalamic obesity - a real-life data study. Pituitary. 2024;27(5):685\u201392. https:\/\/doi.org\/10.1007\/s11102-024-01429-5.","journal-title":"Pituitary"},{"issue":"3","key":"744_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/cen.15262","volume":"103","author":"X Wang","year":"2025","unstructured":"Wang X, Ma H, Wang F, Long H, Li C, Nie M, et al. The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery. Clin Endocrinol (Oxf). 2025;103(3):359\u201365. https:\/\/doi.org\/10.1111\/cen.15262.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"744_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.aed.2025.03.004","volume":"12","author":"S Brijmohan","year":"2025","unstructured":"Brijmohan S, Mullally JA. Successful Treatment of Hypothalamic Obesity with Tirzepatide. AACE Endocrinol Diabetes. 2025;12(1):30\u20133. https:\/\/doi.org\/10.1016\/j.aed.2025.03.004.","journal-title":"AACE Endocrinol Diabetes"},{"issue":"10","key":"744_CR36","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2174\/1871530322666220509225637","volume":"22","author":"E Sani","year":"2022","unstructured":"Sani E, Prato GD, Zenti MG, Bordugo A, Trombetta M, Bonora E. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report. Endocr Metab Immune Disord Drug Targets. 2022;22(10):1053\u20137. https:\/\/doi.org\/10.2174\/1871530322666220509225637.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"744_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/cen.14583","volume":"96","author":"NBH Ng","year":"2022","unstructured":"Ng NBH, Low YW, Rajgor DD, Low JM, Lim YY, Loke KY, et al. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Clin Endocrinol (Oxf). 2022;96(2):144\u201354. https:\/\/doi.org\/10.1111\/cen.14583.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"744_CR38","doi-asserted-by":"publisher","first-page":"1528457","DOI":"10.3389\/fendo.2024.1528457","volume":"15","author":"A Koceva","year":"2024","unstructured":"Koceva A, Mlekus Kozamernik K, Janez A, Herman R, Ferjan S, Jensterle M. Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review. Front Endocrinol (Lausanne). 2024;15:1528457. https:\/\/doi.org\/10.3389\/fendo.2024.1528457.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"744_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-21-0972","volume":"186","author":"K Huynh","year":"2022","unstructured":"Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687\u2013700. https:\/\/doi.org\/10.1530\/EJE-21-0972.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"744_CR40","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/oby.2008.56","volume":"16","author":"A Astrup","year":"2008","unstructured":"Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson\u2019s or Alzheimer\u2019s disease. Obes (Silver Spring). 2008;16(6):1363\u20139. https:\/\/doi.org\/10.1038\/oby.2008.56.","journal-title":"Obes (Silver Spring)"},{"issue":"9653","key":"744_CR41","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","volume":"372","author":"A Astrup","year":"2008","unstructured":"Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(08)61525-1.","journal-title":"Lancet"},{"issue":"6","key":"744_CR42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","volume":"12","author":"CL Roth","year":"2024","unstructured":"Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):380\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(24)00087-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"744_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2512275","volume":"395","author":"JL Miller","year":"2026","unstructured":"Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026;395(2):138\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2512275.","journal-title":"N Engl J Med"},{"issue":"7","key":"744_CR44","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11695-022-06079-9","volume":"32","author":"P Faucher","year":"2022","unstructured":"Faucher P, Carette C, Jannot AS, Gatta-Cherifi B, Van Straaten A, Piquet MA, et al. Five-Year Changes in Weight and Diabetes Status After Bariatric Surgery for Craniopharyngioma-Related Hypothalamic Obesity: a Case-Control Study. Obes Surg. 2022;32(7):2321\u201331. https:\/\/doi.org\/10.1007\/s11695-022-06079-9.","journal-title":"Obes Surg"},{"key":"744_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/5584_2020_511","volume":"1307","author":"A Zenno","year":"2021","unstructured":"Zenno A, Nadler EP. Surgical Treatment of Type 2 Diabetes Mellitus in Youth. Adv Exp Med Biol. 2021;1307:321\u201330. https:\/\/doi.org\/10.1007\/5584_2020_511.","journal-title":"Adv Exp Med Biol"},{"key":"744_CR46","unstructured":"Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers. 2020."},{"key":"744_CR47","unstructured":"Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder. 2022."},{"key":"744_CR48","doi-asserted-by":"publisher","unstructured":"Thaker VGE, Grishman EK, Erenler F, Kelsey MM, Morgan R, Harris EH, Gan HW, Oosterom J, Lee H, Mohamed Z, Farooqi IS. SAT-711 Efficacy and safety of once-daily oral bivamelagon in acquired hypothalamic obesity: Results from a double-blind, multicenter, placebo-controlled, randomized phase 2 Trial. J Endocr Soc. 2025. https:\/\/doi.org\/10.1210\/jendso\/bvaf149.143.","DOI":"10.1210\/jendso\/bvaf149.143"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00744-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00744-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00744-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:38:20Z","timestamp":1784882300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00744-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00744-1","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"65"}}